Understanding the Legal Landscape with Semaglutide
Jul 5, 2023
auto_awesome
Legal expert discusses lawsuits and issues surrounding compounded semaglutide, patent protections, FDA warnings, trademarks, and compliance for medical spas. The podcast also covers the importance of working with reputable compounding pharmacies and legal considerations in healthcare marketing.
Importance of understanding trademark guidelines and avoiding misleading advertising with compounded semaglutide.
Significance of working with FDA-compliant compounding pharmacies to prevent legal complications from non-approved substances.
Deep dives
Understanding the Legal Implications of Semaglutide and Ozempic
The podcast delves into the legal implications surrounding semaglutide and Ozempic, focusing on the FDA-approved medications and the actions taken by manufacturers to protect their investments. It highlights the distinction between using compounded versions and FDA-approved drugs, emphasizing the importance of adhering to trademark guidelines and avoiding misleading advertising when utilizing compounding pharmacies.
Challenges with Compounded Versions and FDA Warnings
The episode discusses the complexities related to compounding pharmacies creating drugs not FDA-approved, citing an FDA warning about using a different base version of semaglutide. It underscores the significance of working with trustworthy compounding pharmacies to ensure adherence to FDA regulations and avoiding complications arising from using non-approved substances for treatments.
Legal Concerns and Best Practices for Medical Spas
The conversation addresses legal concerns around trademark infringement and unfair competition due to the use of brand names for compounded versions. It stresses the importance of accurately representing treatments, avoiding claims of FDA approval for compounded drugs, and conducting due diligence when sourcing medications to maintain compliance and safeguard against potential lawsuits or intellectual property disputes.
This week, AmSpa CEO, Alex R. Thiersch, JD, speaks with Patrick O’Brien, JD, of AmSpa and ByrdAdatto, to discuss the legal concerns with compounded semaglutide and its name-brand drugs. They talk about the basic legal implications of Ozempic and recent lawsuits, compounding pharmacy issues and general guidelines for navigating this area of the law. Their conversation includes:
How compounding pharmacies began compounding semaglutide;
Patent protections for the name-brand manufacturer;
Semaglutide salts and FDA warnings about base ingredients;
The recent lawsuits and the issues at play;
Trademarks, advertising and claims;
How your medical spa can stay compliant when offering compounded semaglutide;
And more!
Read more about the ongoing lawsuits filed by Novo Nordisk, maker of Ozempic and Wegovy, at the AmSpa Now blog. Stay tuned for new updates on the subject as more info becomes available.
This episode of Medical Spa Insider is sponsored by RepeatMD. Visit https://www.repeatmd.com/ to learn more!
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode